{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:38:53Z","timestamp":1791463133703,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T00:00:00Z","timestamp":1454544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Heart Blood and Lung Institute, National Institutes of Health, Bethesda","award":["U34-HL119582"],"award-info":[{"award-number":["U34-HL119582"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      von Willebrand disease (\n                      <jats:styled-content style=\"fixed-case\">VWD<\/jats:styled-content>\n                      ) is the most common congenital bleeding disorder. In women, menorrhagia is the most common bleeding symptom, and is disabling with iron deficiency anaemia, high health cost and poor quality of life. Current hormonal and non\u2010hormonal therapies are limited by ineffectiveness and intolerance. Few data exist regarding von Willebrand factor (\n                      <jats:styled-content style=\"fixed-case\">VWF<\/jats:styled-content>\n                      ), typically prescribed when other treatments fail. The lack of effective therapy for menorrhagia remains the greatest unmet healthcare need in women with\n                      <jats:styled-content style=\"fixed-case\">VWD<\/jats:styled-content>\n                      . Better therapies are needed to treat women with menorrhagia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a survey of US haemophilia treatment centres (\n                      <jats:styled-content style=\"fixed-case\">HTC<\/jats:styled-content>\n                      s) and a literature review using medical subject heading (Me\n                      <jats:styled-content style=\"fixed-case\">SH<\/jats:styled-content>\n                      ) search terms \u2018von Willebrand factor,\u2019 \u2018menorrhagia\u2019 and \u2018von Willebrand disease\u2019 to assess the use of\n                      <jats:styled-content style=\"fixed-case\">VWF<\/jats:styled-content>\n                      in menorrhagia. Analysis was by descriptive statistics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 83 surveys distributed to\n                      <jats:styled-content style=\"fixed-case\">HTC MD<\/jats:styled-content>\n                      s, 20 (24.1%) provided sufficient data for analysis. Of 1321 women with\n                      <jats:styled-content style=\"fixed-case\">VWD<\/jats:styled-content>\n                      seen during 2011\u20132014, 816 (61.8%) had menorrhagia, for which combined oral contraceptives, tranexamic acid and desmopressin were the most common first\u2010line therapies for menorrhagia, whereas\n                      <jats:styled-content style=\"fixed-case\">VWF<\/jats:styled-content>\n                      was third\u2010line therapy reported in 13 women (1.6%). Together with data from 88 women from six published studies,\n                      <jats:styled-content style=\"fixed-case\">VWF<\/jats:styled-content>\n                      safely reduced menorrhagia in 101 women at a dose of 33\u2013100 IU kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      on day 1\u20136 of menstrual cycle.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This represents the largest\n                      <jats:styled-content style=\"fixed-case\">VWD<\/jats:styled-content>\n                      menorrhagia treatment experience to date.\n                      <jats:styled-content style=\"fixed-case\">VWF<\/jats:styled-content>\n                      safely and effectively reduces menorrhagia in women with\n                      <jats:styled-content style=\"fixed-case\">VWD<\/jats:styled-content>\n                      . A prospective clinical trial is planned to confirm these findings.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.12898","type":"journal-article","created":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T02:56:19Z","timestamp":1454554579000},"page":"397-402","source":"Crossref","is-referenced-by-count":48,"title":["Von Willebrand factor for menorrhagia: a survey and literature review"],"prefix":"10.1111","volume":"22","author":[{"given":"M. V.","family":"Ragni","sequence":"first","affiliation":[{"name":"University of Pittsburgh Medical Center Pittsburgh PA USA"},{"name":"Hemophilia Center of Western Pennsylvania Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Machin","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. M.","family":"Malec","sequence":"additional","affiliation":[{"name":"Hemophilia Center of Western Pennsylvania Pittsburgh PA USA"},{"name":"Children's Hospital of Pittsburgh Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. H.","family":"James","sequence":"additional","affiliation":[{"name":"Duke University Medical Center Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Kessler","sequence":"additional","affiliation":[{"name":"Georgetown University Medical Center Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. A.","family":"Konkle","sequence":"additional","affiliation":[{"name":"BloodWorks Northwest Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"Kouides","sequence":"additional","affiliation":[{"name":"Rochester General Hosp. Rochester NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. T.","family":"Neff","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. S.","family":"Philipp","sequence":"additional","affiliation":[{"name":"Rutgers Robert Wood Johnson Medical School New Brunswick NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Brambilla","sequence":"additional","affiliation":[{"name":"Research Triangle Institute International Rockville MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.2.454.454"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02146.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01643.x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00342.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.474"},{"key":"e_1_2_9_7_1","volume-title":"NICE Clinical Guidelines 44: Heavy Menstrual Bleeding","author":"National Institute for Health and Clinical Excellence","year":"2007"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02269.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365516409060511"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02315.x"},{"key":"e_1_2_9_11_1","volume-title":"Management of Anovulatory Bleeding","author":"ACOG","year":"2000"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07610.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01847.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.7.2515"},{"key":"e_1_2_9_15_1","first-page":"171","volume-title":"Menstrual Disorders","author":"Schlesinger KW","year":"2006"},{"key":"e_1_2_9_16_1","first-page":"3","article-title":"Baseline characteristics of females with bleeding disorders receiving care in the US. HTC Network","volume":"3","author":"Byams VR","year":"2010","journal-title":"Natl Conf Blood Disorders Pub Health"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00678.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00313.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01655.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649813"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2004.00305.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-04-0274"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1255445"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-479527"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629873"},{"key":"e_1_2_9_26_1","unstructured":"Medical Product Safety.In Healthy People 2020. Available athttp:\/\/www.healthypeople.gov\/2020\/topics-objectives\/blood-disorders-and-blood-safety. Accessed August 21 2015"},{"key":"e_1_2_9_27_1","first-page":"237","article-title":"Clinical trial opportunities in hemostasis and thrombosis. Proceedings of the NHLBI State\u2010of\u2010the\u2010Science Symposium","volume":"87","author":"Cines DB","year":"2012","journal-title":"Am J Med"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02916.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12496"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01901.x"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000257"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.12.017"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2000.tb13225.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12898","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12898","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.12898","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T12:56:39Z","timestamp":1693400199000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.12898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,4]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/hae.12898"],"URL":"https:\/\/doi.org\/10.1111\/hae.12898","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,4]]}}}